Merck & Co., Inc.
Holdings as of Mar 31, 2026 · filed May 13, 2026
| # | Holding | Value | % Port. | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Moderna Inc | $117256052 | 33.56% | — | Held |
| 2 | Personalis Inc | $89466287 | 25.60% | — | Held |
| 3 | Kymera Therapeutics Inc | $64313623 | 18.40% | — | Held |
| 4 | Entrada Therapeutics Inc | $21955872 | 6.28% | — | Held |
| 5 | Eikon Therapeutics Inc | $17633326 | 5.05% | — | NEW BUY |
| 6 | Aktis Oncology Inc | $17046379 | 4.88% | — | NEW BUY |
| 7 | Alector Inc | $7623297 | 2.18% | — | Held |
| 8 | Sutro Biopharma Inc | $6784263 | 1.94% | — | Held |
| 9 | Evaxion Biotech A/S | $4516549 | 1.29% | — | Held |
| 10 | Viridian Therapeutics Inc | $1827178 | 0.52% | — | Held |
| 11 | Xilio Therapeutics Inc | $891309 | 0.26% | — | NEW BUY |
| 12 | Carisma Therapeutics Inc | $47880 | 0.01% | — | Held |
| 13 | Neuphoria Therapeutics Inc | $40810 | 0.01% | — | Held |
| 14 | Tuhura Biosciences | $34807 | 0.01% | +5495 | +39.39% |
Closed last quarter
Xilio Therapeutics Inc
Holdings disclosed quarterly to the SEC on Form 13-F and may be up to 45 days old. Values as reported. For research only — not investment advice.